These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21208841)

  • 61. Current targeted therapies in the treatment of advanced colorectal cancer: a review.
    Moriarity A; O'Sullivan J; Kennedy J; Mehigan B; McCormick P
    Ther Adv Med Oncol; 2016 Jul; 8(4):276-93. PubMed ID: 27482287
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quantitative imaging biomarkers: the application of advanced image processing and analysis to clinical and preclinical decision making.
    Prescott JW
    J Digit Imaging; 2013 Feb; 26(1):97-108. PubMed ID: 22415112
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers.
    Ahn JW; Kim HS; Yoon JK; Jang H; Han SM; Eun S; Shim HS; Kim HJ; Kim DJ; Lee JG; Lee CY; Bae MK; Chung KY; Jung JY; Kim EY; Kim SK; Chang J; Kim HR; Kim JH; Lee MG; Cho BC; Lee JH; Bang D
    Genome Med; 2014; 6(2):18. PubMed ID: 24576404
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab.
    Ortiz-Morales MJ; Toledano-Fonseca M; Mena-Osuna R; Cano MT; Gómez-España A; Haba-Rodríguez JR; Rodríguez-Ariza A; Aranda E
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804826
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma.
    Amano T; Iijima H; Shinzaki S; Tashiro T; Iwatani S; Tani M; Otake Y; Yoshihara T; Sugimoto A; Egawa S; Yamaguchi S; Kinoshita K; Araki M; Hirao M; Sakakibara Y; Hiyama S; Ogawa H; Nagaike K; Murata J; Komori M; Okuda Y; Kizu T; Tsujii Y; Hayashi Y; Inoue T; Takahashi H; Mizushima T; Morii E; Takehara T
    BMC Cancer; 2021 Aug; 21(1):978. PubMed ID: 34465291
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Construction and Analysis of ceRNA Network and Patterns of Immune Infiltration in Colon Adenocarcinoma Metastasis.
    Chang Z; Huang R; Fu W; Li J; Ji G; Huang J; Shi W; Yin H; Wang W; Meng T; Huang Z; Wei Q; Qin H
    Front Cell Dev Biol; 2020; 8():688. PubMed ID: 32850813
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis.
    Torén W; Ansari D; Andersson R
    Cancer Cell Int; 2018; 18():217. PubMed ID: 30602942
    [TBL] [Abstract][Full Text] [Related]  

  • 69. European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer.
    Stanel SC; Sjöberg J; Salmonson T; Foggi P; Caleno M; Melchiorri D; Gravanis I; Tzogani K; Pignatti F
    ESMO Open; 2017; 2(2):e000190. PubMed ID: 28761750
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.
    Makondi PT; Chu CM; Wei PL; Chang YJ
    PLoS One; 2017; 12(7):e0180616. PubMed ID: 28749961
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.
    Au TH; Wang K; Stenehjem D; Garrido-Laguna I
    J Gastrointest Oncol; 2017 Jun; 8(3):387-404. PubMed ID: 28736627
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity.
    Ahn HM; Ryu J; Song JM; Lee Y; Kim HJ; Ko D; Choi I; Kim SJ; Lee JW; Kim S
    Theranostics; 2017; 7(3):594-613. PubMed ID: 28255353
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effect of vascular endothelial growth factor-1 expression on survival of advanced colorectal cancer patients.
    Bendardaf R; El-Serafi A; Syrjänen K; Collan Y; Pyrhönen S
    Libyan J Med; 2017 Dec; 12(1):1290741. PubMed ID: 28245709
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.
    Murphy AG; Casey R; Maguire A; Tosetto M; Butler CT; Conroy E; Reynolds AL; Sheahan K; O'Donoghue D; Gallagher WM; Fennelly D; Kennedy BN; O'Sullivan J
    Sci Rep; 2016 Oct; 6():34523. PubMed ID: 27739445
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab.
    Hara M; Nagasaki T; Shiga K; Takahashi H; Takeyama H
    Surg Today; 2017 Apr; 47(4):483-489. PubMed ID: 27549777
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.
    Chen Y; Shi Y; Lin J; Ye YB; Wang XJ; Chen G; Guo ZQ
    Medicine (Baltimore); 2015 Oct; 94(40):e1698. PubMed ID: 26448020
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma.
    Condelli V; Maddalena F; Sisinni L; Lettini G; Matassa DS; Piscazzi A; Palladino G; Amoroso MR; Esposito F; Landriscina M
    Oncotarget; 2015 Sep; 6(26):22298-309. PubMed ID: 26084290
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies.
    Akkad J; Bochum S; Martens UM
    Langenbecks Arch Surg; 2015 Feb; 400(2):129-43. PubMed ID: 25701352
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways.
    Gong B; Liu WW; Nie WJ; Li DF; Xie ZJ; Liu C; Liu YH; Mei P; Li ZJ
    World J Gastroenterol; 2015 Feb; 21(5):1488-97. PubMed ID: 25663768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.